Article

Quality Control Metrics for Whole Blood Transcriptome Analysis in the Parkinson’s Progression Markers Initiative (PPMI)

2021-01-08

Abstract excerpt

The Michael J. Fox Foundation’s Parkinson’s Progression Markers Initiative (PPMI) is an observational study to comprehensively evaluate Parkinson’s disease (PD) patients using imaging, biologic sampling, clinical and behavioural assessments to identify biomarkers of PD progression. As part of this study, we obtained 4,756 whole blood samples from 1,570 subjects at baseline, 0.5, 1, 2, and 3 years from enrollment i...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c857eb28-e439-554b-9705-bdfaadb6ca80
DOI: 10.1101/2021.01.05.21249278

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Quality Control Metrics for Whole Blood Transcriptome Analysis in the Parkinson’s Progression Markers Initiative (PPMI)DOI 10.1101/2021.01.05.21249278Read

The Quest for a Universal Parkinson’s Transcriptomics Signature is Derailed by Inherent Variability between PatientsSemantic proximity Read

Blood transcriptomics reveals a Parkinson’s disease signature and heterogeneous prodromal molecular profiles in isolated RBDSemantic proximity Read

Plasma acellular transcriptome contains Parkinson’s disease signatures that can inform clinical diagnosisSemantic proximity Read

Classification algorithms applied to blood-based transcriptome meta-analysis to predict idiopathic Parkinson's diseaseSemantic proximity Read

Analysis of blood-based gene expression in idiopathic Parkinson diseaseSemantic proximity Read

Low-variance RNAs identify Parkinson's disease molecular signature in blood.Semantic proximity Read

Leveraging blood RNA expression to understand Parkinson’s disease heterogeneity and progressionSemantic proximity Read

Molecular Integration in Neurological Diagnosis (MIND) Parkinson's Disease Inception Cohort Study ProtocolSemantic proximity Read

Characterization of Parkinson’s disease using blood-based biomarkers: A multicohort proteomic analysisSemantic proximity Read

Accelerating Medicines Partnership: Parkinson’s Disease. Genetic ResourceSemantic proximity Read

RETRACTED: A systematic genomic screen of 755 early-onset Parkinson’s patients from the 100,000 Genomes Project increases diagnostic yield and directs clinical pathwaysSemantic proximity Read

Directional Gene-Level Concordance and Methodological Constraints in Blood Transcriptomic and DNA Methylation Studies of Parkinson’s DiseaseSemantic proximity Read